IMR Press / EJGO / Volume 29 / Issue 3 / pii/1630995584613-1278448101

European Journal of Gynaecological Oncology (EJGO) is published by IMR Press from Volume 40 Issue 1 (2019). Previous articles were published by another publisher on a subscription basis, and they are hosted by IMR Press on imrpress.com as a courtesy and upon agreement with S.O.G.

Open Access Original Research
Interval debulking in epithelial ovarian carcinomas: the past, present and the future
Show Less
1 Department of Obstetrics and Gynecology, Cankiri Government Hospital, Cankiri
2 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Baskent University School of Medicine, Maltepe, Ankara
3 Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Hacettepe University School of Medicine, Sihhiye, Ankara (Turkey)
Eur. J. Gynaecol. Oncol. 2008, 29(3), 242–245;
Published: 10 June 2008
Abstract

Primary cytoreductive surgery followed by combination chemotherapy of paclitaxel and cisplatinum is the standard treatment for advanced staged epithelial ovarian cancers. Despite the maximal efforts to increase optimal cytoreductive success rates and related ultra-radical surgeries, five-year survival rates are still poor. Primary cytoreductive surgeries and their radicalities have been criticized since the early nineties. Interval debulking surgery (IDS) and neo-adjuvant chemotherapy (NAC) are the two suggested alternatives to the primary debulking approaches. In this article, the authors summarize and discuss the IDS approach with an associated literature review.
Keywords
Interval debulking surgery
Interval laparotomy
Epithelial ovarian carcinoma
Share
Back to top